Section 232 tariff relief for orphan drugs: Who may qualify

How orphan drugs may qualify for 0% section 232 pharmaceutical tariff relief

Life sciences companies importing orphan drugs and associated pharmaceutical ingredients may qualify for a 0% section 232 tariff rate under new Commerce Department guidance.

A qualifying orphan drug that originates in a jurisdiction identified by the Commerce Department may receive the 0% tariff treatment without an urgent U.S. health need determination. When that jurisdiction-based pathway is unavailable, an urgent U.S. health need may provide a separate route to tariff relief.

Determining eligibility begins with the product itself. The Commerce Department defines the orphan drug category as a drug or biological product designated for one or more rare diseases or conditions “for which all approved indications … are for one or more such rare diseases or conditions.”

Determining whether an orphan drug qualifies

The following three questions can help companies assess whether an orphan drug may qualify for 0% section 232 tariff treatment:

Section 232 tariff relief for development-stage products

The guidance creates a new Harmonized Tariff Schedule of the United States heading for pharmaceutical articles and associated ingredients that are solely for use in clinical trials, research and development, or other noncommercial applications. Imports meeting the requirements of that provision receive an additional 0% section 232 tariff rate.

Depending on the circumstances, development-stage imports may have other potential tariff-relief pathways, including the U.S. tariff provision for qualifying prototypes.

The provision may be particularly relevant for biotech and other life sciences companies that import materials for clinical trials, research and development, and other activities well before commercialization. Depending on a company’s development and manufacturing processes, those imports can include clinical-trial supplies and materials used in producing investigational therapies.

For companies importing products before commercialization, intended use can therefore be an important factor in identifying where the separate 0% section 232 tariff treatment may apply.

How pharmaceutical ingredients affect section 232 tariff treatment

The section 232 framework extends beyond finished pharmaceutical products. The Commerce Department defines “pharmaceutical articles” to include finished pharmaceutical products, active pharmaceutical ingredients (APIs) and key starting materials for active pharmaceutical ingredients. Inactive ingredients and excipients are excluded from that definition.

For life sciences companies, understanding the treatment of materials throughout the supply chain may require looking beyond finished products. Depending on the company’s products and manufacturing processes, those materials can include:

• Drug substances
• Biological materials
• Specialized intermediates
• Cell and gene therapy manufacturing inputs

Looking at more than the finished product can help companies identify potential section 232 tariff treatment elsewhere in the manufacturing supply chain. Understanding how those materials are classified and used can clarify where pharmaceutical tariffs may apply and where 0% tariff treatment may be available.

Evaluating potential section 232 tariff relief

Companies can focus on several areas when evaluating how the new guidance may affect their section 232 tariff exposure:

Assessing section 232 pharmaceutical tariff exposure

For orphan drug manufacturers and other life sciences companies, determining whether an imported product qualifies for favorable treatment may be as important as understanding the applicable tariff rate itself. The analysis can depend on the product, its origin and, in some cases, its intended use or an urgent U.S. health need.

Applying those factors across a company’s product pipeline can help identify where tariff relief may be available and where section 232 exposure remains.